The Food and Drug Administration will select an advisory panel to review Cell Therapeutics Inc.'s (Nasdaq: CTIC) lymphoma treatment pixantrone due to safety concerns. The stock price plummeted 34 cents to 72 cents.
FDA Advisory Panel To Review Cell Therapeutics' Pixantrone
February 08, 2010 at 12:29 PM EST
